Gene Therapy for Neurodegenerative Diseases

Migration, Crosslink

📖

Gene Therapy for Neurodegenerative Diseases

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-gene-therapy-neurodege

📖 Wiki Page

therapeutic1490 wordssynced 2026-04-02

Gene Therapy for Neurodegenerative Diseases

Introduction

flowchart TD classDef gene fill:#0a1f0a,stroke:#4caf50,color:#e0e0e0 classDef protein fill:#0a1929,stroke:#2196f3,color:#e0e0e0 classDef disease fill:#2d0f0f,stroke:#e91e63,color:#e0e0e0 classDef pathway fill:#3e2200,stroke:#ff9800,color:#e0e0e0 classDef mechanism fill:#1a0a1f,stroke:#9c27b0,color:#e0e0e0 classDef therapeutic fill:#e0f2f1,stroke:#009688,color:#0d0d1a Gene_Therapy_for_Neurodegenerative_Disea["Gene Therapy for Neurodegenerative Diseases"] -->|"references"| AADC["AADC"] Gene_Therapy_for_Neurodegenerative_Disea["Gene Therapy for Neurodegenerative Diseases"] -->|"references"| BACE1["BACE1"] Gene_Therapy_for_Neurodegenerative_Disea["Gene Therapy for Neurodegenerative Diseases"] -->|"references"| BDNF["BDNF"] Gene_Therapy_for_Neurodegenerative_Disea["Gene Therapy for Neurodegenerative Diseases"] -->|"references"| HTT["HTT"] Gene_Therapy_for_Neurodegenerative_Disea["Gene Therapy for Neurodegenerative Diseases"] -->|"references"| TH["TH"] Gene_Therapy_for_Neurodegenerative_Disea["Gene Therapy for Neurodegenerative Diseases"] -->|"references"| TARDBP["TARDBP"] Gene_Therapy_for_Neurodegenerative_Disea["Gene Therapy for Neurodegenerative Diseases"] -->|"references"| TREM2["TREM2"]

...

Gene Therapy for Neurodegenerative Diseases

Introduction

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Gene Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Disease</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>PD/Gaucher</td>
</tr>
<tr>
<td class="label">PARK2 (Parkin)</td>
<td>Early-onset PD</td>
</tr>
<tr>
<td class="label">PINK1</td>
<td>PD</td>
</tr>
<tr>
<td class="label">CHCHD10</td>
<td>ALS/FTD</td>
</tr>
<tr>
<td class="label">FXN</td>
<td>Friedreich's ataxia</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Tofersen</td>
<td>SOD1</td>
</tr>
<tr>
<td class="label">Nusinersen</td>
<td>SMN1</td>
</tr>
<tr>
<td class="label">Inotersen</td>
<td>TTR</td>
</tr>
<tr>
<td class="label">IONIS-HTTRx</td>
<td>[HTT](/proteins/huntingtin)</td>
</tr>
<tr>
<td class="label">Serotype</td>
<td>CNS Target</td>
</tr>
<tr>
<td class="label">AAV9</td>
<td>[Neurons](/entities/neurons), [astrocytes](/entities/astrocytes)</td>
</tr>
<tr>
<td class="label">AAV2</td>
<td>Neurons</td>
</tr>
<tr>
<td class="label">AAV1</td>
<td>Motor neurons</td>
</tr>
<tr>
<td class="label">AAV-PHP.B</td>
<td>CNS-wide</td>
</tr>
<tr>
<td class="label">AAV-PHP.eB</td>
<td>CNS-wide</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Vector</td>
</tr>
<tr>
<td class="label">NCT04480350</td>
<td>AAV</td>
</tr>
<tr>
<td class="label">NCT03788707</td>
<td>AAV</td>
</tr>
<tr>
<td class="label">NCT05838430</td>
<td>AAV</td>
</tr>
<tr>
<td class="label">Product</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Upstaza</td>
<td>AADC</td>
</tr>
<tr>
<td class="label">ABBV-951</td>
<td>TH/AADC/GCH1</td>
</tr>
<tr>
<td class="label">AAV-GAD</td>
<td>GAD65/67</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Tofersen</td>
<td>SOD1</td>
</tr>
<tr>
<td class="label">ION363</td>
<td>C9orf72</td>
</tr>
<tr>
<td class="label">WVE-004</td>
<td>C9orf72</td>
</tr>
<tr>
<td class="label">ASO-Targeted</td>
<td>FUS</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Biomarker</td>
</tr>
<tr>
<td class="label">Target engagement</td>
<td>Protein levels in CSF</td>
</tr>
<tr>
<td class="label">Disease modification</td>
<td>[Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL)</td>
</tr>
<tr>
<td class="label">Imaging</td>
<td>PET tracers</td>
</tr>
<tr>
<td class="label">Clinical</td>
<td>Motor/cognitive scores</td>
</tr>
<tr>
<td class="label">Product</td>
<td>Disease</td>
</tr>
<tr>
<td class="label">Upstaza</td>
<td>AADC deficiency</td>
</tr>
<tr>
<td class="label">Zolgensma</td>
<td>SMA</td>
</tr>
<tr>
<td class="label">Spinraza</td>
<td>SMA</td>
</tr>
<tr>
<td class="label">Tofersen</td>
<td>SOD1-ALS</td>
</tr>
</table>

Gene therapy represents a transformative approach to treating neurodegenerative diseases by delivering therapeutic genetic material to target cells in the central nervous system. Unlike small molecule drugs or biologics that require repeated administration, gene therapy offers the potential for long-lasting or even curative effects through a single treatment. Recent advances in viral vector technology, delivery methods, and gene editing tools have accelerated clinical development across Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and other neurodegenerative conditions["1"]. [@gowing2024]

Gene Therapy Approaches

Gene Replacement

Gene replacement therapy delivers a functional copy of a disease-causing gene to compensate for loss-of-function mutations. This approach is particularly relevant for autosomal recessive diseases and conditions where increasing protein expression provides therapeutic benefit. [@kuiper2023]

Applications in Neurodegeneration: [@pickaroliver2019]

Gene Silencing

RNA interference (RNAi) and antisense oligonucleotide (ASO) technologies enable selective reduction of toxic protein expression. This approach is ideal for gain-of-function mutations and diseases driven by protein overexpression[2].

Key Technologies:

Antisense Oligonucleotides (ASOs): Single-stranded DNA analogs that bind target RNA via base pairing, promoting RNase H degradation
RNAi: Small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) that trigger sequence-specific mRNA degradation
MicroRNAs (miRNAs): Endogenous regulators that can be engineered as therapeutic agents

Clinical Applications:

Gene Editing

CRISPR-Cas9 and related technologies enable precise modification of genomic DNA, offering potential for correcting disease-causing mutations or disrupting toxic gene expression[3].

Editing Strategies:

Knockout: Disrupt toxic gene expression

Knock-in: Correct mutations or add protective variants

Regulation: Modulate gene expression levels

Insertion: Deliver therapeutic genes to safe harbor loci

Emerging Approaches:

Base editing: Single-nucleotide changes without double-strand breaks
Prime editing: All types of edits including insertions and deletions
Epigenetic editing: Modulate gene expression without altering DNA sequence

Viral Vectors for CNS Delivery

Adeno-Associated Vectors (AAV)

AAV vectors are the dominant platform for CNS gene therapy due to their favorable safety profile and long-term expression[4].

Serotype Tropism:

Key Advantages:

Non-pathogenic and low immunogenicity
Long-term expression (years)
Broad CNS tropism (with engineered capsids)
Multiple serotypes available for targeting

Challenges:

Limited packaging capacity (~4.7 kb)
Pre-existing immunity in humans
Requires circumventing blood-brain barrier

Lentiviral Vectors

Lentiviral vectors can deliver larger genetic payloads and integrate into the host genome, providing stable expression.

Applications:

ex vivo gene therapy (cells modified then transplanted)
Non-dividing cell transduction
Long-term expression requirements

Non-Viral Delivery

Alternative Approaches:

Lipid nanoparticles (LNPs)
Polymer-based nanoparticles
Electroporation
Focused ultrasound-mediated delivery

Disease-Specific Applications

Alzheimer's Disease

Gene Therapy Targets:

Amyloid-related genes:

[APP](/entities/app-protein): Reduce amyloid production via siRNA
BACE1: Knockdown of [beta-secretase](/entities/bace1)

Tau-related genes:

[MAPT](/proteins/tau): Reduce tau expression
[GSK3B](/entities/gsk3-beta): Modulate kinase activity

Neuroprotective genes:

BDNF: Deliver brain-derived neurotrophic factor
NGF: Nerve growth factor for cholinergic neurons
APOE4: Deliver protective APOE2 allele

Clinical Trials:

Parkinson's Disease

Gene Therapy Approaches:

Dopamine restoration:

AADC (aromatic L-amino acid decarboxylase): Convert L-DOPA to dopamine
TH (tyrosine hydroxylase): Rate-limiting step in dopamine synthesis
GCH1: Tetrahydrobiopterin synthesis cofactor

Neuroprotection:

GDNF: Glial cell line-derived neurotrophic factor
Neurturin: GDNF family member
[α-synuclein](/proteins/alpha-synuclein) silencing

Disease-modifying:

LRRK2 inhibition
GBA gene augmentation
Parkin/PINK1 delivery

Approved and Advanced Programs:

Amyotrophic Lateral Sclerosis (ALS)

Gene Therapy Strategies:

SOD1 silencing (Tofersen - approved):

ASO delivered intrathecally
Reduces SOD1 protein by ~60%
Demonstrated biomarker and clinical benefit

[C9orf72](/entities/c9orf72) targeting:

Reduce repeat-associated non-ATG translation
Target toxic dipeptide repeats
siRNA and ASO approaches in development

FUS, TARDBP targeting:

ASOs in clinical trials
Reduce mutant FUS/TDP-43 expression

Neuroprotective factors:

AAV-SOD1: Deliver antioxidant genes
GDNF delivery to motor neurons

Clinical Pipeline:

Huntington's Disease

Gene Therapy Approaches:

HTT gene silencing:

Reduce mutant huntingtin protein
Multiple ASOs in development
Allele-selective approaches in research

Neuroprotective strategies:

BDNF delivery
CRISPR editing of mutant allele

Clinical Status:

IONIS-HTTRx (Roche/Ionis): Completed Phase I/II
VHS-001 (Voyager): IND-cleared
Multiple programs in preclinical development

Delivery Challenges and Solutions

Blood-Brain Barrier Crossing

The [BBB](/entities/blood-brain-barrier) remains a major hurdle for CNS gene therapy. Current strategies include:

Direct CNS injection:

Intraparenchymal
Intrathecal
Intraventricular

BBB-disrupting techniques:

Focused ultrasound
Mannitol
Chemical permeabilizers

Engineered vectors:

AAV-PHP.B and variants
Receptor-mediated transcytosis
Antibody-directed delivery

Immune Response

Mitigation Strategies:

Immunosuppression before/after delivery
Engineered capsids with reduced immunogenicity
Empty capsid removal
Route of administration optimization

Dose Limiting Toxicities

Liver toxicity: Monitor liver enzymes
Off-target effects: Careful design of targeting sequences
Insertional mutagenesis: Use integration-deficient vectors
Inflammation: Anti-inflammatory co-treatment

Biomarkers for Gene Therapy

Efficacy Markers

Safety Monitoring

Immune response markers
Liver function tests
CSF inflammatory markers
Vector distribution imaging

Regulatory Considerations

Approved Gene Therapies for Neurological Conditions

Key Regulatory Agencies

FDA (US): Center for Biologics Evaluation and Research (CBER)
EMA (EU): Committee for Advanced Therapies (CAT)
Accelerated approval pathways available

Future Directions

Emerging Technologies

Viral vector evolution:

Novel capsids with improved CNS tropism
Reduced immunogenicity
Larger capacity vectors

Gene editing advances:

In vivo editing with lipid nanoparticles
Base editing for precise corrections
Epigenetic modulation

Combination approaches:

Gene therapy + small molecules
Multiple gene targets
Disease-modifying + symptomatic

Challenges to Overcome

Long-term safety data
Cost and accessibility
Manufacturing scale-up
Patient selection criteria
Regulatory framework evolution

External Links

[ClinicalTrials.gov: Gene Therapy Neurodegeneration](https://clinicaltrials.gov/search?cond=neurodegeneration&intr=gene+therapy)
[FDA: Cellular & Gene Therapy Products](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products)
[ASGCT: American Society of Gene & Cell Therapy](https://www.asgct.org/)
[Gene Therapy Net](https://www.genetherapynet.com/)

References

[Unknown, Gowing G, Svendsen S, Svendsen CN. Gene therapy for neurodegenerative diseases: progress and prospects. Nat Rev Neurol. 2024;20(5):293-307 (2024)](https://pubmed.ncbi.nlm.nih.gov/38514656/)

[Unknown, Kuiper EJ, Broekman MD. RNA therapeutics for neurodegenerative disease. Brain. 2023;146(8):3123-3137 (2023)](https://pubmed.ncbi.nlm.nih.gov/37194288/)

[Unknown, Pickar-Oliver A, Gersbach CA. The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019;20(8):490-507 (2019)](https://pubmed.ncbi.nlm.nih.gov/31180058/)

[Unknown, Wang D, Gao G. AAV vector delivery to the central nervous system. Mol Ther. 2024;32(1):45-59 (2024)](https://pubmed.ncbi.nlm.nih.gov/38097654/)

[Unknown, Tofersen for SOD1-ALS: FDA approval package. Amyotroph Lateral Scler Frontotemporal Degener. 2023;24(Suppl 1):1-12 (2023)](https://pubmed.ncbi.nlm.nih.gov/37458234/)

[Unknown, Coune PG, Schneider BL, Aebischer P. Parkinson's disease: gene therapies. Nat Rev Neurol. 2022;18(3):143-156 (2022)](https://pubmed.ncbi.nlm.nih.gov/35087235/)

[Unknown, Leavitt BR, Tabrizi SJ. Antisense oligonucleotides for Huntington's disease: where are we now? Nat Rev Neurol. 2024;20(2):71-72 (2024)](https://pubmed.ncbi.nlm.nih.gov/38200267/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — 0.55 · Target: TREM2
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Cryptic Exon Silencing Restoration](/hypothesis/h-4fabd9ce) — 0.66 · Target: TARDBP
[Cross-Seeding Prevention Strategy](/hypothesis/h-eea667a9) — 0.65 · Target: TARDBP
[Glycine-Rich Domain Competitive Inhibition](/hypothesis/h-7e846ceb) — 0.59 · Target: TARDBP
[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — 0.58 · Target: TREM2
[Palmitoylation-Targeted BACE1 Trafficking Disruptors](/hypothesis/h-441b25ba) — 0.55 · Target: BACE1

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-gene-therapy-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-gene-therapy-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-bc07424b13b3
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-gene-therapy-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

191

Outgoing

283

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Gene Therapy for Neurodegenerative Diseases

Gene Therapy for Neurodegenerative Diseases

Introduction

Gene Therapy for Neurodegenerative Diseases

Introduction

Gene Therapy Approaches

Gene Replacement

Gene Silencing

Gene Editing

Viral Vectors for CNS Delivery

Adeno-Associated Vectors (AAV)

Lentiviral Vectors

Non-Viral Delivery

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Delivery Challenges and Solutions

Blood-Brain Barrier Crossing

Immune Response

Dose Limiting Toxicities

Biomarkers for Gene Therapy

Efficacy Markers

Safety Monitoring

Regulatory Considerations

Approved Gene Therapies for Neurological Conditions

Key Regulatory Agencies

Future Directions

Emerging Technologies

Challenges to Overcome

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

Gene Therapy for Neurodegenerative Diseases

Gene Therapy for Neurodegenerative Diseases

Introduction

Gene Therapy for Neurodegenerative Diseases

Introduction

Gene Therapy Approaches

Gene Replacement

Gene Silencing

Gene Editing

Viral Vectors for CNS Delivery

Adeno-Associated Vectors (AAV)

Lentiviral Vectors

Non-Viral Delivery

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Delivery Challenges and Solutions

Blood-Brain Barrier Crossing

Immune Response

Dose Limiting Toxicities

Biomarkers for Gene Therapy

Efficacy Markers

Safety Monitoring

Regulatory Considerations

Approved Gene Therapies for Neurological Conditions

Key Regulatory Agencies

Future Directions

Emerging Technologies

Challenges to Overcome

See Also

External Links

References

Related Hypotheses

💬 Discussion